Finally, the finding that DYRK1A inhibition by pharmacological and genetic approaches contributes to reverse the abnormal neurogenesis in NPCs and neurons derived from Twin-DS-iPSCs, allows a proof-of-principle for potential screening tests using iPSC technology (Hibaoui & Feki, 2012) and should provide the basis for designing new therapeutic approaches for patients with DS. Here, DYRK1A is linked to Dravet syndrome.